<DOC>
	<DOCNO>NCT00422227</DOCNO>
	<brief_summary>The purpose study compare efficacy etanercept usual disease-modifying anti-rheumatic drug ( DMARD ) therapy treatment moderate severe rheumatoid arthritis ( RA ) 16 week Asia Pacific region .</brief_summary>
	<brief_title>Study Comparing Etanercept With Usual DMARD Therapy Subjects With Rheumatoid Arthritis Asia Pacific Region</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Diagnosis RA Currently receive adequate dose methotrexate ( MTX ) treatment RA Active RA time screen baseline Previous current treatment etanercept ( ETN ) , tumor necrosis factoralpha inhibitor , biologic agent Concurrent treatment DMARD , MTX , screen Receipt DMARD , MTX , within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>